Central nervous system lymphoma associated with natalizumab

Angelika Na; Nick Hall; Bhadrakant Kavar; John King

doi:10.1016/j.jocn.2013.10.018

Central nervous system lymphoma associated with natalizumab

J Clin Neurosci. 2014 Jun;21(6):1068-70. doi: 10.1016/j.jocn.2013.10.018. Epub 2013 Nov 9.

Authors

Angelika Na¹, Nick Hall¹, Bhadrakant Kavar¹, John King²

Affiliations

¹ Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia.
² Department of Neurology, Royal Melbourne Hospital, Grattan Street, Parkville, Melbourne, VIC 3050, Australia. Electronic address: John.king@mh.org.au.

PMID: 24373819
DOI: 10.1016/j.jocn.2013.10.018

Abstract

Patients with primary central nervous system lymphoma (PCNSL) after treatment with natalizumab have been considered co-incidental. We report another case of PCNSL in a patient where the explosive onset suggests a causal link.

Keywords: Lymphoma; Multiple sclerosis; Natalizumab.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects*
Central Nervous System Neoplasms / chemically induced*
Central Nervous System Neoplasms / diagnosis*
Fatal Outcome
Humans
Lymphoma / chemically induced*
Lymphoma / diagnosis*
Male
Natalizumab

Substances

Antibodies, Monoclonal, Humanized
Natalizumab